Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood marker may shed light on stubborn heel pain

NCT ID NCT07785453

Knowledge-focused Sponsor: Kanuni Sultan Suleyman Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This study looks at whether a protein called CTGF/CCN2, found in the blood, is linked to chronic plantar fasciitis—a condition causing persistent heel pain. Researchers will compare CTGF levels in people with the condition to those without, and see if higher levels relate to worse pain or reduced foot function. The goal is to better understand the condition and potentially identify a useful biomarker.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If a link is found, CTGF levels might become a biomarker to help diagnose or monitor plantar fasciitis, potentially guiding treatment decisions.
What could go wrong
This is a small observational study, so it can only show associations, not cause and effect. Results may not apply to all patients or lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18-65 years, including patients with chronic plantar fasciitis and asymptomatic controls without clinical or ultrasonographic findings of plantar fasciitis.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-65 years. * Written informed consent. * For the patient group: chronic plantar heel pain for at least 3 months, pain during the first steps in the morning or after prolonged rest, tenderness over the medial calcaneal tubercle, and clinical and ultrasonographic findings consistent with chronic plantar fasciitis. * For the control group: asymptomatic individuals without a previous diagnosis or clinical and ultrasonographic findings of plantar fasciitis. Exclusion Criteria: * Tarsal tunnel syndrome, calcaneal stress fracture, plantar fascia rupture, Achilles tendinopathy, heel fat pad syndrome, plantar fibromatosis, or other foot conditions causing plantar heel pain. * Diabetes mellitus. * Inflammatory rheumatic diseases or gout. * Chronic kidney or liver disease. * Malignancy. * Active infection or autoimmune disease * Pregnancy. * Previous foot or ankle surgery. * Corticosteroid injection, platelet-rich plasma (PRP), prolotherapy, extracorporeal shock wave therapy (ESWT), or other interventional treatment to the affected heel within the previous 3 months. * Serious systemic conditions that may affect serum CTGF/CCN2 levels.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plantar fasciitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plantar fasciitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plantar fasciitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.